{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:40:00Z","timestamp":1791830400905,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012555","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000}}],"reference-count":125,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012555.pub2","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T12:26:42Z","timestamp":1537792002000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults"],"prefix":"10.1002","volume":"2018","author":[{"given":"Anna","family":"Sutherland","sequence":"first","affiliation":[{"name":"Katharine House Hospice; Mandeville Road Aynho Road, Adderbury Banbury UK OX17 3NL"},{"name":"Cochrane Fellowship, Cochrane UK; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Naessens","sequence":"additional","affiliation":[{"name":"Oxford Radcliffe Trust\/Health Education Thames Valley; Palliative Care; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Plugge","sequence":"additional","affiliation":[{"name":"Cochrane UK; Summertown Pavilion 18 - 24 Middle Way Oxford UK OX2 7LG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Ware","sequence":"additional","affiliation":[{"name":"Cochrane UK; Summertown Pavilion 18 - 24 Middle Way Oxford UK OX2 7LG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Head","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford; Cochrane ENT; UK Cochrane Centre, Summertown Pavilion 18 - 24 Middle Way Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"Burton","sequence":"additional","affiliation":[{"name":"Cochrane UK; Summertown Pavilion 18 - 24 Middle Way Oxford UK OX2 7LG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bee","family":"Wee","sequence":"additional","affiliation":[{"name":"Churchill Hospital; Nuffield Department of Medicine and Sir Michael Sobell House; Old Road Headington Oxford UK OX3 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD012555.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","article-title":"Risk model-guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial","volume":"2","author":"Clemons","year":"2016","journal-title":"JAMA Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012555.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00520-015-2944-x","article-title":"Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors","volume":"24","author":"Dranitsaris","year":"2016","journal-title":"Supportive Care in Cancer"},{"issue":"3","key":"10.1002\/14651858.CD012555.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/ecc.12260","article-title":"QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist","volume":"24","author":"Liu","year":"2015","journal-title":"European Journal of Cancer Care"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Tan L Liu J Liu X Chen J Yan Z Yang H Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting Journal of Experimental and Clinical Cancer Research 2009 131","DOI":"10.1186\/1756-9966-28-131"},{"issue":"7","key":"10.1002\/14651858.CD012555.pub2-BIB0005|cit5","first-page":"544","article-title":"Antiemetic effect of low dose olanzapine in solid tumor chemotherapy","volume":"20","author":"Lu","year":"2013","journal-title":"Chinese Journal of Cancer Prevention and Treatment"},{"issue":"3","key":"10.1002\/14651858.CD012555.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study","volume":"47","author":"Mizukami","year":"2014","journal-title":"Journal of Pain and Symptom Management"},{"issue":"1","key":"10.1002\/14651858.CD012555.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00520-016-3386-9","article-title":"Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study","volume":"25","author":"Mukhopadhyay","year":"2017","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0008|cit8","first-page":"1","article-title":"Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study","volume":"25","author":"Mukhopadhyay","year":"2016","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0009|cit9","first-page":"S99","article-title":"Olanzapine, concurrent chemo-radiation patients and chemotherapy induced nausea and vomiting: the surprise continues","volume":"22(1 suppl. 1)","author":"Mukhopadhyay","year":"2014","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0010|cit10","first-page":"S126","article-title":"Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients; a randomized controlled study","volume":"23(1 suppl. 1)","author":"Mukhopadhyay","year":"2015","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/j.clinthera.2015.05.312","article-title":"Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients","volume":"1","author":"Mukhopadhyay","year":"2015","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD012555.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00520-016-3416-7","article-title":"Erratum to: Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study","volume":"25","author":"Mukhopadhyay","year":"2017","journal-title":"Supportive Care in Cancer"},{"issue":"23","key":"10.1002\/14651858.CD012555.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V126.23.1910.1910","article-title":"A randomized trial of olanzapine and palonosetron versus infused ondansetron for the treatment of chemotherapy induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation","volume":"126","author":"Nakagaki","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012555.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00520-016-3445-2","article-title":"A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation","volume":"25","author":"Nakagaki","year":"2017","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0018|cit15","first-page":"S47","article-title":"Treatment of cancer related anorexia with megestrol acetate and olanzapine","volume":"18","author":"Navari","year":"2009","journal-title":"Psycho-Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0015|cit16","first-page":"971","article-title":"Treatment of cancer related anorexia with olanzapine and megestrol acetate","volume":"17(7)","author":"Navari","year":"2009","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0016|cit17","doi-asserted-by":"crossref","first-page":"9576","DOI":"10.1200\/jco.2008.26.15_suppl.9576","article-title":"Treatment of cancer-related anorexia with olanzapine and megestrol acetate","volume":"26(15 suppl)","author":"Navari","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0017|cit18","doi-asserted-by":"crossref","unstructured":"Navari R Brenner M Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial Supportive Care in Cancer 2010 951 6","DOI":"10.1007\/s00520-009-0739-7"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0019|cit19","first-page":"S47","article-title":"Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","volume":"20","author":"Navari","year":"2012","journal-title":"Supportive Care in Cancer"},{"issue":"15 suppl 1","key":"10.1002\/14651858.CD012555.pub2-BIB0020|cit20","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","volume":"30","author":"Navari","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Navari R Nagy C Gray S The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Supportive Care in Cancer 2013 1655 63","DOI":"10.1007\/s00520-012-1710-6"},{"issue":"12","key":"10.1002\/14651858.CD012555.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00761-016-0134-1","article-title":"Olanzapine: extension of preventive options for nausea and vomiting after highly emetogenic chemotherapy","volume":"22","author":"Ahlborn","year":"2016","journal-title":"Chemotherapie Onkologe"},{"issue":"41","key":"10.1002\/14651858.CD012555.pub2-BIB0023|cit23","first-page":"43","article-title":"Olanzapine prevents nausea and vomiting from chemotherapy","volume":"160","author":"Mammatas","year":"2016","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Navari R Qin R Ruddy J Liu H Powell S Bajaj M Olanzapine for the prevention of chemotherapy-induced nausea and vomiting New England Journal of Medicine 2016 134 42","DOI":"10.1056\/NEJMoa1515725"},{"issue":"(29 suppl. 1)","key":"10.1002\/14651858.CD012555.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/jco.2015.33.29_suppl.176","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Navari","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/1735-1995.192504","article-title":"Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy","volume":"21","author":"Nikbakhsh","year":"2016","journal-title":"Journal of Research in Medical Sciences"},{"issue":"(15S Part I)","key":"10.1002\/14651858.CD012555.pub2-BIB0027|cit27","first-page":"516","article-title":"A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting [abstract no. 9633]","volume":"27","author":"Shumway","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012555.pub2-BIB0028|cit28","first-page":"233","article-title":"A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy induced nausea and vomiting","volume":"8","author":"Shumway","year":"2015","journal-title":"Journal of Pain Management"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12013-014-0489-0","article-title":"Effectiveness of olanzapine combined with ondansetron in the prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer","volume":"72","author":"Wang","year":"2015","journal-title":"Cell Biochemistry and Biophysics"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0030|cit30","unstructured":"Zhang D Aprepitant, olanzapine, palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (AOPDPCINV) clinicaltrials.gov\/ct2\/show\/NCT02484911"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0031|cit31","unstructured":"Zhao J Li X Jinghua G Li Y Li J Shi Y Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy - induced nausea and vomiting Modern Oncology 2014 1941 3"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"(no pagination)","DOI":"10.1155\/2016\/3439707","article-title":"The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India","volume":"-","author":"Babu","year":"2016","journal-title":"Chemotherapy Research and Practice"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0033|cit33","unstructured":"EUCTR2015-002294-38-DK DANSAC-pilot: an open label pilot study to investigate the tolerability and efficacy of olanzapine in patients with advanced cancer not receiving chemotherapy or irradiation apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-002294-38-DK"},{"issue":"1","key":"10.1002\/14651858.CD012555.pub2-BIB0034|cit34","first-page":"87","article-title":"Guideline for the prevention of breakthrough and treatment of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients","volume":"68","author":"Flank","year":"2015","journal-title":"Canadian Journal of Hospital Pharmacy"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0035|cit35","first-page":"S157","article-title":"Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting (CIV) in children: a retrospective, multi-centre review","volume":"22(1 Suppl. 1)","author":"Flank","year":"2014","journal-title":"Supportive Care in Cancer"},{"issue":"3","key":"10.1002\/14651858.CD012555.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/pbc.25286","article-title":"Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review","volume":"62","author":"Flank","year":"2015","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0037|cit37","first-page":"S241","article-title":"Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-centre review","volume":"61","author":"Flank","year":"2014","journal-title":"Pediatric Blood and Cancer"},{"issue":"8","key":"10.1002\/14651858.CD012555.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/oby.2010.6","article-title":"Increased food intake and energy expenditure following administration of olanzapine to healthy men","volume":"18","author":"Fountaine","year":"2010","journal-title":"Obesity (Silver Spring, Md.)"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0039|cit39","first-page":"76","article-title":"COMFORT trial-comparison of olanzapin and metoclopramid for treatment of breakthrough emesis: first experiences of this trial in progress","volume":"35","author":"Guntsch","year":"2012","journal-title":"Onkologie"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"(no pagination)","DOI":"10.1200\/JCO.2016.34.15_suppl.10111","article-title":"A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin","volume":"34","author":"Hashimoto","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0041|cit41","unstructured":"ISRCTN58624349 Olanzapine (ZYPREXA) versus haloperidol (Novo-Peridol) for the relief of nausea and vomiting (N&V) in patients with advanced cancer www.isrctn.com\/ISRCTN58624349?q=&filters=conditionCategory:Signs%20and%20Symptoms,trialStatus:Stopped&sort=relevance&offset=23&totalResults=23&page=3&pageSize=10&searchType=basic-search"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0042|cit42","first-page":"S79","article-title":"Olanzapine for post-chemotherapy dysgeusia and anorexia: The unidentified saviour?","volume":"21","author":"Kwatra","year":"2013","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0043|cit43","first-page":"S104","article-title":"A pilot study comparing the addition of olanzapine or aprepitant in an antiemetic regimen for highly emetogenic chemotherapyPediatric Blood and Cancer","volume":"62","author":"Long","year":"2015","journal-title":"American Society of Pediatric Hematology\/Oncology, ASPHO"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0044|cit44","unstructured":"NCT02097823 Pilot study of olanzapine and aprepitant to prevent nausea and vomiting in children receiving chemotherapy NCT02097823 www.clinicaltrials.gov"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0045|cit45","first-page":"219","article-title":"Anorexia in concurrent chemoradiation patients: Can olanzapine calm down the monster?","volume":"56(5 SUPPL. 1)","author":"Mukhopadhyay","year":"2012","journal-title":"Indian Journal of Physiology and Pharmacology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0046|cit46","unstructured":"Nakashima K Murakami H A phase II study of aprepitant, palonosetron, dexamethasone and olanzapine for the prevention of cisplatin-based hemotherapy-induced nausea and vomiting for thoracic malignancy upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&action=brows&recptno=R000020267&type=summary&language=E 2015"},{"issue":"27(supp)","key":"10.1002\/14651858.CD012555.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"e20536","DOI":"10.1200\/jco.2009.27.15_suppl.e20536","article-title":"Treatment of chemotherapy-induced breakthrough nausea and vomiting","volume":"1","author":"Navari","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0048|cit48","first-page":"S1","article-title":"Treatment of chemotherapy-induced breakthrough nausea and vomiting","volume":"19(supp)","author":"Navari","year":"2010","journal-title":"Psycho-oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0049|cit49","first-page":"111","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting: a randomized Phase III trial","volume":"21","author":"Navari","year":"2012","journal-title":"Psycho-oncology"},{"issue":"(15 SUPPL. 1)","key":"10.1002\/14651858.CD012555.pub2-BIB0050|cit50","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): a randomized phase III trial","volume":"28","author":"Navari","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Navari R Gray S Kerr A Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial The Journal of Supportive Oncology 2011 188 95","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0052|cit52","first-page":"S81","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV): a randomized trial","volume":"18","author":"Navari","year":"2010","journal-title":"Supportive Care in Cancer"},{"issue":"15 suppl. 1","key":"10.1002\/14651858.CD012555.pub2-BIB0054|cit53","article-title":"Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment","volume":"33","author":"Navari","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012555.pub2-BIB0053|cit54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.12788\/jcso.0245","article-title":"Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting","volume":"14","author":"Navari","year":"2016","journal-title":"The Journal of Community and Supportive Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0055|cit55","unstructured":"NCT00124930 Study comparing olanzapine with haloperidol for the relief of nausea and vomiting in patients with advanced cancer clinicaltrials.gov\/ct2\/show\/NCT00124930"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0056|cit56","unstructured":"NCT01148264 Comparison of olanzapine and metoclopramide for treatment of breakthrough emesis (COMFORT) www.clinicaltrials.gov"},{"issue":"6","key":"10.1002\/14651858.CD012555.pub2-BIB0057|cit57","first-page":"491","article-title":"Is the addition of olanzapine effective in restoration of CINV prevention in non-responders to standard antiemetic therapy? A retrospective controlled study","volume":"38","author":"Slimano","year":"2016","journal-title":"International Journal of Clinical Pharmacy"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0058|cit58","unstructured":"Yanai T Yamamoto N A double-blind randomized phase II study of olanzapine 10mg versus 5mg for highly emetogenic chemotherapy-induced nausea and vomiting rctportal.niph.go.jp\/en\/detail?trial_id=UMIN000014214 2015"},{"issue":"5","key":"10.1002\/14651858.CD012555.pub2-BIB0059|cit59","first-page":"681","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic antineoplastic chemotherapy","volume":"52","author":"Chasick","year":"2012","journal-title":"Journal of the American Pharmacists Association"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0060|cit60","unstructured":"ChiCTR-TTRCC-14004093 Olanzapine versus aprepitant for the prevention of high dose cisplatin-induced nausea and vomiting: a randomized phase III trial apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-TTRCC-14004093"},{"issue":"15 Supplement 1","key":"10.1002\/14651858.CD012555.pub2-BIB0061|cit61","first-page":"(no pagination)","article-title":"A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"35","author":"Jeon","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012555.pub2-BIB0062|cit62","first-page":"452","article-title":"Clinical observation of olanzepine combined with granisterom and hexadecadrol prevent nausea vomit induced by chemoradiotherapy","volume":"13","author":"Mao","year":"2011","journal-title":"Chinese Journal of Medicinal Guide"},{"issue":"7","key":"10.1002\/14651858.CD012555.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.11569\/wcjd.v24.i7.1117","article-title":"Olanzapine combined with normal antiemetic drugs in patients on solid tumor chemotherapy: antiemetic effect and impact on quality of life","volume":"24","author":"Meng","year":"2016","journal-title":"World Chinese Journal of Digestology"},{"issue":"15 Supplement 1","key":"10.1002\/14651858.CD012555.pub2-BIB0064|cit64","article-title":"Olanzapine versus aprepitant in the prevention of chemotherapy induced nausea and vomiting (CINV) in breast cancer patients","volume":"35","author":"Mukesh","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"2 Supplement 1","key":"10.1002\/14651858.CD012555.pub2-BIB0065|cit65","first-page":"S72","article-title":"Olanzapine and omeprazole combination is simple, safe and effective for delayed nausea and vomiting control in adjuvant chemotherapy for early stage breast cancer","volume":"25","author":"Nguyen","year":"2017","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0066|cit66","first-page":"7406","article-title":"Effectiveness of olanzapine in prevention of chemotherapy induced nausea and vomiting","volume":"6","author":"Wang","year":"2012","journal-title":"Clin J Clin (full journal title not available)"},{"issue":"(2 Supplement 1","key":"10.1002\/14651858.CD012555.pub2-BIB0067|cit67","first-page":"S632017","article-title":"A randomized, double-blind, placebo-controlled phase iii study evaluating olanzapine 5mg combined with standard antiemetic therapy for the prevention of CINV in patients receiving cisplatin-based chemotherapy","volume":"25","author":"Abe","year":"2017","journal-title":"Supportive Care in Cancer. Conference: 2017 International MASCC\/ISOO Symposium"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0068|cit68","unstructured":"ChiCTR-TTRCC-14004093 Olanzapine versus aprepitant for the prevention of high-dose cisplatin-induced nausea and vomiting: a randomised phase III trial apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-TTRCC-14004093 (accessed 28 September 2017)"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0069|cit69","article-title":"A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: J-SUPPORT 1604","volume":"-","author":"Hashimoto","year":"2017","journal-title":"rctportal.niph.go.jp\/en\/detail?trial_id=UMIN000024676"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0070|cit70","first-page":"v543","article-title":"1607TiP - J-FORCE study: a randomized, double-blind, placebo-controlled phase III study evaluating olanzapine (5 mg) combined with standard antiemetic therapy","volume":"28(suppl_5)","author":"Hashimoto","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0071|cit71","unstructured":"JPRN-UMIN000010317 Efficacy of olanzapine for relief of nausea with incomplete bowel obstruction in advanced cancer patient: pragmatic randomized controlled trial apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000010317"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.clinthera.2017.05.053","article-title":"Low dose vs. standard dose adjuvant olanzapine in chemotherapy induced nausea and vomiting: a prospective, randomized, double blinded, controlled study","volume":"39(8 Supplement","author":"Mukhopadhyay","year":"2017","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0073|cit73","first-page":"S248","article-title":"Comparison of efficacy, safety and sedation with two doses of add on olanzapine in chemotherapy induced nausea and vomiting: a randomized controlled pilot study","volume":"24(1 Supplement","author":"Mukhopadhyay","year":"2016","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0074|cit74","first-page":"S69","article-title":"Low dose olanzapine in chemotherapy induced nausea and vomiting: a balance game between sedation and nausea?","volume":"25(2 Supplement","author":"Mukhopadhyay","year":"2017","journal-title":"Supportive Care in Cancer: International MASCC\/ISOO Symposium"},{"issue":"2","key":"10.1002\/14651858.CD012555.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jjco\/hyu191","article-title":"A double-blind randomized phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy","volume":"45","author":"Nagashima","year":"2015","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0076|cit76","unstructured":"NCT02290470 Olanzapine against delayed nausea and vomiting in women receiving carboplatin plus paclitaxel clinicaltrials.gov\/ct2\/show\/NCT02290470"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0077|cit77","unstructured":"NCT02400866 A randomized study of olanzapine for the prevention of CINV in patients receiving moderately emetogenic chemotherapy clinicaltrials.gov\/ct2\/show\/NCT02400866"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0078|cit78","unstructured":"NCT02635984 Study of FOND versus FOND+O for the prevention of CIV in hematology patients receiving highly emetogenic chemotherapy regimens clinicaltrials.gov\/ct2\/show\/NCT02635984"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0079|cit79","unstructured":"NCT02939287 Aprepitant versus olanzapine with high dose melphalan clinicaltrials.gov\/ct2\/show\/NCT02939287"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0080|cit80","unstructured":"NCT02970643 Proof-of-concept trial of palonosetron and olanzapine without dexamethasone for the prevention of CIN clinicaltrials.gov\/ct2\/show\/NCT02970643"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0081|cit81","unstructured":"NCT03079219 Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients clinicaltrials.gov\/ct2\/show\/NCT03079219"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0082|cit82","unstructured":"NCT03137121 Olanzapine for the treatment of chronic nausea and\/or vomiting in advanced cancer patients clinicaltrials.gov\/ct2\/show\/NCT03137121"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0083|cit83","unstructured":"Anonymous Zyprexa 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg coated tablets. Zyprexa Velotab 5 mg, 10 mg, 15 mg, and 20 mg orodispersible tablets www.medicines.org.uk\/emc\/medicine\/614"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0084|cit84","unstructured":"British National Formulary www.evidence.nhs.uk\/formulary\/bnf\/current\/4-central-nervous-system\/42-drugs-used-in-psychoses-and-related-disorders\/421-antipsychotic-drugs\/second-generation-antipsychotic-drugs\/olanzapine"},{"issue":"1","key":"10.1002\/14651858.CD012555.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting","volume":"19","author":"Burke","year":"2011","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0086|cit86","first-page":"S64","article-title":"Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in south east Asia: a multinational study","volume":"25(2 Supplement","author":"Chanthawong","year":"2017","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"877","DOI":"10.18549\/PharmPract.2017.01.877","article-title":"Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis","volume":"15(1)","author":"Chelkeba","year":"2017","journal-title":"Pharmacy Practice"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","article-title":"Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis","volume":"24(5)","author":"Chiu","year":"2016","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00520-015-3000-6","article-title":"Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review","volume":"24(2)","author":"Chow","year":"2016","journal-title":"Supportive Care in Cancer"},{"issue":"5","key":"10.1002\/14651858.CD012555.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","article-title":"Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen","year":"2007","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0091|cit91","unstructured":"Veritas Health Innovation Covidence 2017"},{"issue":"11","key":"10.1002\/14651858.CD012555.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009420.pub3","article-title":"Levomepromazine for nausea and vomiting in palliative care","author":"Cox","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0093|cit93","unstructured":"Deeks J J Higgins J P Altman D G (editors) on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins J P T, Churchill R, Chandler J, Cumpston M S (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"7109","key":"10.1002\/14651858.CD012555.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0095|cit95","unstructured":"US Food Drug Administration (FDA) ZYPREXA\u00ae olanzapine tablets ZYPREXA\u00ae ZYDIS\u00ae olanzapine orally disintegrating tablets ZYPREXA\u00ae intramuscular olanzapine for Injection www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4399b1-05%20(Zyprexa%20(olanzapine)%20Labeling).pdf"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0096|cit96","first-page":"243-59","article-title":"Treating nausea and vomiting in palliative care: a review","volume":"6","author":"Glare","year":"2011","journal-title":"Clinical Interventions in Aging"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0097|cit97","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0098|cit98","unstructured":"GraphPad Software Inc GraphPad 2017"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0101|cit101","unstructured":"Higgins J P Altman D G Sterne J A C (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins J P T, Churchill R, Chandler J, Cumpston M S (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD012555.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"e002515","DOI":"10.1136\/bmjopen-2012-002515","article-title":"Are emergency admissions in palliative cancer care always necessary? Results from a descriptive study","volume":"3","author":"Hjermstad","year":"2013","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00520-014-2138-y","article-title":"Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review","volume":"22(4)","author":"Hocking","year":"2014","journal-title":"Supportive Care in Cancer"},{"issue":"2","key":"10.1002\/14651858.CD012555.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/109662103764978506","article-title":"Olanzapine for intractable nausea in palliative care patients","volume":"6","author":"Jackson","year":"2003","journal-title":"Journal of Palliative Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012555.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp-2015-311049","article-title":"Antipsychotic medications for the treatment of delirium: a systematic review and meta-analysis of randomised controlled trials","volume":"87","author":"Kishi","year":"2016","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012555.pub2-BIB0106|cit106","first-page":"9","article-title":"Impact of CINV","volume":"9","author":"Kris","year":"2011","journal-title":"Clinical Advances in Hematology and Oncology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0107|cit107","article-title":"Efficacy of olanzapine for prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis","volume":"35(15 Supplemen","author":"Kumar","year":"2017","journal-title":"Journal of Clinical Oncology. Conference"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/acem.12842","article-title":"A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department","volume":"23","author":"Martel","year":"2016","journal-title":"Society for Academic Emergency Medicine"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0109|cit109","unstructured":"EMC Nytol One-A-Night www.medicines.org.uk\/emc\/medicine\/19778"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0110|cit110","unstructured":"EMC Zofran Tablets 4 mg and 8 mg www.medicines.org.uk\/emc\/medicine\/17650\/spc"},{"issue":"7","key":"10.1002\/14651858.CD012555.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012555.pub2-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006271.pub3","article-title":"Haloperidol for the treatment of nausea and vomiting in palliative care patients","author":"Murray-Brown","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012555.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","article-title":"Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents","volume":"73","author":"Navari","year":"2013","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD012555.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/(SICI)1099-1611(200001\/02)9:1<84::AID-PON440>3.0.CO;2-T","article-title":"Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report","volume":"9","author":"Pirl","year":"2000","journal-title":"Psycho-oncology"},{"issue":"1","key":"10.1002\/14651858.CD012555.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1049909112441241","article-title":"Olanzapine: palliative medicine update","volume":"30","author":"Prommer","year":"2012","journal-title":"American Journal of Hospice & Palliative Medicine"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0116|cit116","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0117|cit117","unstructured":"Sch\u00fcnemann H J Oxman A D Higgins J P Vist G E Glasziou P Guyatt G H Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins J P T, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0118|cit118","unstructured":"Sch\u00fcnemann H J Oxman A D Higgins J P Vist G E Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins J P T, Churchill R, Chandler J, Cumpston M S (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD012555.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"58-69","DOI":"10.1016\/j.jpainsymman.2005.06.007","article-title":"A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease","volume":"31","author":"Solano","year":"2006","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"1","key":"10.1002\/14651858.CD012555.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","article-title":"Symptom prevalence in patients with incurable cancer: a systematic review","volume":"31","author":"Teunissen","year":"2007","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00520-015-2778-6","article-title":"Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials","volume":"23(8)","author":"Vorst","year":"2015","journal-title":"Supportive Care in Cancer"},{"issue":"22","key":"10.1002\/14651858.CD012555.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.7314\/APJCP.2014.15.22.9587","article-title":"Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy","volume":"15","author":"Wang","year":"2014","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bcp.13242","article-title":"Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis","volume":"83(7)","author":"YangT","year":"2017","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD012555.pub2-BIB0125|cit125","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2017.02.017","article-title":"Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis","volume":"112","author":"Yoodee","year":"2017","journal-title":"Critical Reviews in Oncology\/Hematology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012555.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T20:26:08Z","timestamp":1629231968000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012555.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":125,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012555.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]}}}